GSK managed to beat analysts’ revenue predictions ... driven once again by its shingles vaccine Shingrix and HIV therapies sold under the ViiV Healthcare joint venture. Shingrix grew 19% to ...
On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £500 million from £1.3 billion in the first quarter of 2022, and GSK is expecting the ...
Breakthrough Adjuvant AB-801 Secures“Bioprocessing Excellence in Taiwan” HonorTAIPEI, Taiwan, March 13, 2025 (GLOBE NEWSWIRE) ...
GlaxoSmithKline Pharmaceuticals Limited is ... In 2022-23, the Company launched Shingrix, a vaccine for prevention of herpes zoster (HZ) and postherpetic neuralgia (PHN) in adults who are 50 ...
Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was up ...
After hours: March 14 at 7:47:25 PM EDT Loading Chart for GSK ...
After hours: 7:59:44 pm GMT-5 Loading Chart for GSK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback